Blinatumomab after standard treatment for B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial is studying how well the drug blinatumomab works for adults with B-cell acute lymphoblastic leukemia (B-ALL) when it is given after the first phase of treatment. It looks at patient data to understand real-world outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) on or after December 1, 2022.
- You have not received blinatumomab as part of a clinical trial before.
- You are willing and able to give consent for your information to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests whether the drug blinatumomab, given after a stem cell transplant, can help prevent high-risk B-ALL from coming back. It is for people who have already had a transplant and meet certain health criteria.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
Hear when a new B-Cell Acute Lymphoblastic Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.